[go: up one dir, main page]

IL144096A0 - Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) - Google Patents

Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)

Info

Publication number
IL144096A0
IL144096A0 IL14409699A IL14409699A IL144096A0 IL 144096 A0 IL144096 A0 IL 144096A0 IL 14409699 A IL14409699 A IL 14409699A IL 14409699 A IL14409699 A IL 14409699A IL 144096 A0 IL144096 A0 IL 144096A0
Authority
IL
Israel
Prior art keywords
inhibition
factor
activity
processes
preparation
Prior art date
Application number
IL14409699A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99100002A external-priority patent/EP1016663A1/fr
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL144096A0 publication Critical patent/IL144096A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14409699A 1999-01-02 1999-12-23 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) IL144096A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99100002A EP1016663A1 (fr) 1999-01-02 1999-01-02 Dérivés de l'acide malonique, procédé pour leur préparation, leur utilisation comme médicaments et compositions les contenant (inhibiteurs du facteur Xa )
EP99119537 1999-10-01
PCT/EP1999/010340 WO2000040571A1 (fr) 1999-01-02 1999-12-23 Nouveaux derives d'acide malonique, procedes de preparation de ces derives, leur utilisation et compositions pharmaceutiques les contenant (inhibition de l'activite du facteur xa)

Publications (1)

Publication Number Publication Date
IL144096A0 true IL144096A0 (en) 2002-05-23

Family

ID=26152843

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14409699A IL144096A0 (en) 1999-01-02 1999-12-23 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)

Country Status (17)

Country Link
US (1) US6395737B1 (fr)
EP (1) EP1140878A1 (fr)
JP (1) JP2002534420A (fr)
KR (1) KR20010101355A (fr)
CN (1) CN1332734A (fr)
AU (1) AU3043100A (fr)
BR (1) BR9916732A (fr)
CA (1) CA2358578A1 (fr)
CZ (1) CZ20012379A3 (fr)
HK (1) HK1041700A1 (fr)
HU (1) HUP0105437A3 (fr)
ID (1) ID29979A (fr)
IL (1) IL144096A0 (fr)
NO (1) NO20012983D0 (fr)
PL (1) PL349343A1 (fr)
TR (1) TR200101903T2 (fr)
WO (1) WO2000040571A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69924527T2 (de) 1999-01-02 2006-02-09 Sanofi-Aventis Deutschland Gmbh Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen
EP1127884A1 (fr) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Dérivés de l'acide malonique, procédés pour leur préparation, leur utilisation comme inhibiteur du facteur XA et compositions les contenants
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
HUE025683T2 (hu) 2002-12-03 2016-04-28 Pharmacyclics Llc VIIA faktor inhibitor 2-(2-hidroxi-bifenil-3-il)-1H-benzoimidazol-5-karboxamidin-származékok
US9828324B2 (en) 2010-10-20 2017-11-28 Sirrus, Inc. Methylene beta-diketone monomers, methods for making methylene beta-diketone monomers, polymerizable compositions and products formed therefrom
US9279022B1 (en) 2014-09-08 2016-03-08 Sirrus, Inc. Solution polymers including one or more 1,1-disubstituted alkene compounds, solution polymerization methods, and polymer compositions
EP3208287A1 (fr) 2010-10-20 2017-08-23 Sirrus, Inc. Synthèse de malonates de méthylène par récupération rapide en présence d'un agent de transfert d'énergie
US9249265B1 (en) 2014-09-08 2016-02-02 Sirrus, Inc. Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions
US10414839B2 (en) 2010-10-20 2019-09-17 Sirrus, Inc. Polymers including a methylene beta-ketoester and products formed therefrom
WO2013055984A1 (fr) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Composés tétrahydroisoquinolines substitués en tant qu'inhibiteurs du facteur xia
PH12014500625B1 (en) 2011-10-14 2018-12-12 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
MX370256B (es) 2011-10-19 2019-12-09 Sirrus Inc Monomeros multifuncionales, procedimientos para la preparación de monomeros multifuncionales, composiciones polimerizables y productos formados a partir de los mismos.
WO2013149168A1 (fr) 2012-03-30 2013-10-03 Bioformix, Inc. Articles stratifiés et composites et systèmes polymérisables pour les produire
US9181365B2 (en) 2012-03-30 2015-11-10 Sirrus, Inc. Methods for activating polymerizable compositions, polymerizable systems, and products formed thereby
CA2869115A1 (fr) 2012-03-30 2013-10-03 Bioformix Inc. Formulations d'encre et de revetement et systemes polymerisables pour la production desdites formulations
WO2013181600A2 (fr) 2012-06-01 2013-12-05 Bioformix Inc. Matériau optique et objets formés à partir de celui-ci
TR201807316T4 (tr) 2012-10-12 2018-06-21 Bristol Myers Squibb Co Bir faktör XIa inhibitörünün kristalli formları.
EP2906541B1 (fr) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Composés de tetrahydroisoquinoline substitués par guanidine et amine en tant qu'inhibiteurs de factor xia
EP2906552B1 (fr) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Composés de tetrahydroisoquinoline substitués par guanidine en tant qu'inhibiteurs de factor xia
EP2920231B1 (fr) 2012-11-16 2020-05-06 Sirrus, Inc. Systèmes et procédés de liaison de matières plastiques
EP3712928A1 (fr) 2012-11-30 2020-09-23 Sirrus, Inc. Compositions composites pour applications électroniques
WO2014110388A1 (fr) 2013-01-11 2014-07-17 Bioformix Inc. Procédé d'obtention de malonate de méthylène par l'intermédiaire de la voie du bis(hydroxyméthyl)malonate
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
SI3099687T1 (en) 2014-01-31 2018-08-31 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (fr) 2014-01-31 2018-03-10
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
EP3189047B1 (fr) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamides macrocycliques qui sont des inhibiteurs de fxia
US9315597B2 (en) 2014-09-08 2016-04-19 Sirrus, Inc. Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures
US9416091B1 (en) 2015-02-04 2016-08-16 Sirrus, Inc. Catalytic transesterification of ester compounds with groups reactive under transesterification conditions
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10501400B2 (en) 2015-02-04 2019-12-10 Sirrus, Inc. Heterogeneous catalytic transesterification of ester compounds with groups reactive under transesterification conditions
US9334430B1 (en) 2015-05-29 2016-05-10 Sirrus, Inc. Encapsulated polymerization initiators, polymerization systems and methods using the same
US9217098B1 (en) 2015-06-01 2015-12-22 Sirrus, Inc. Electroinitiated polymerization of compositions having a 1,1-disubstituted alkene compound
US9518001B1 (en) 2016-05-13 2016-12-13 Sirrus, Inc. High purity 1,1-dicarbonyl substituted-1-alkenes and methods for their preparation
US10196481B2 (en) 2016-06-03 2019-02-05 Sirrus, Inc. Polymer and other compounds functionalized with terminal 1,1-disubstituted alkene monomer(s) and methods thereof
US10428177B2 (en) 2016-06-03 2019-10-01 Sirrus, Inc. Water absorbing or water soluble polymers, intermediate compounds, and methods thereof
US9617377B1 (en) 2016-06-03 2017-04-11 Sirrus, Inc. Polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes
US9567475B1 (en) 2016-06-03 2017-02-14 Sirrus, Inc. Coatings containing polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (fr)
DE242404C (fr)
DK425382A (da) * 1981-09-25 1983-03-26 Wellcome Found Fremgangsmaade til fremstilling af amider
AU8868991A (en) * 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives
IT1254883B (it) * 1992-04-16 1995-10-11 Italfarmaco Spa Tetrapeptidi parzialmente modificati e retroinvertiti, analoghi di frammenti della proteina c-reattiva.
CZ245994A3 (en) * 1993-02-10 1995-10-18 Pentapharm Ag Piperazides of substituted phenylalanine derivatives as thrombin inhibitors
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
CZ296439B6 (cs) * 1994-04-26 2006-03-15 Selectide Corporation Inhibitory faktoru Xa
AU3107795A (en) * 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
DE69623038T2 (de) * 1995-12-20 2002-12-12 Aventis Pharmaceuticals Inc., Bridgewater Verfahren zur herstellung von n-acetyl(l)-4-cyanophenylalanin ac-(l)-phe(4-cn)-phe(4-cn)-oh und n-acetyl-(l)-p-amidinophenylalanin-cyclohexylglycin-beta-(3-n-methylpyridinium)-alanin ac-(l)-paph-chg-palme(3)-nh2
AU729910B2 (en) 1997-05-02 2001-02-15 Akzo Nobel N.V. Serine protease inhibitors
AU743881B2 (en) 1997-12-24 2002-02-07 Sanofi-Aventis Deutschland Gmbh Indole derivatives as inhibitors or factor Xa
EP1016663A1 (fr) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Dérivés de l'acide malonique, procédé pour leur préparation, leur utilisation comme médicaments et compositions les contenant (inhibiteurs du facteur Xa )

Also Published As

Publication number Publication date
AU3043100A (en) 2000-07-24
CN1332734A (zh) 2002-01-23
PL349343A1 (en) 2002-07-15
HUP0105437A2 (hu) 2002-05-29
EP1140878A1 (fr) 2001-10-10
ID29979A (id) 2001-10-25
KR20010101355A (ko) 2001-11-14
TR200101903T2 (tr) 2001-11-21
BR9916732A (pt) 2001-09-25
US6395737B1 (en) 2002-05-28
JP2002534420A (ja) 2002-10-15
HK1041700A1 (zh) 2002-07-19
CZ20012379A3 (cs) 2001-09-12
WO2000040571A1 (fr) 2000-07-13
HUP0105437A3 (en) 2003-03-28
NO20012983L (no) 2001-06-15
CA2358578A1 (fr) 2000-07-13
NO20012983D0 (no) 2001-06-15

Similar Documents

Publication Publication Date Title
PL349343A1 (en) Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
IL151459A0 (en) Novel malonic acid derivatives, processes for their preparation, their use as inhibitors of factor xa activity and pharmaceutical compositions containing them
HUP0200863A3 (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them and their use
IL145789A0 (en) Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them
HUP0200190A3 (en) Dimeric compounds and as inhibitors of neuraminidase, process for their preparation and pharmaceutical compositions containing them
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203183A3 (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use
HUP9801045A3 (en) Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation
HUP0204143A3 (en) Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
HUP9801044A3 (en) Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
HUP0002517A3 (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof, pharmaceutical compositions containing them and their use as medicaments
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203385A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0204347A3 (en) Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them and their use
HUP0203471A3 (en) Antithrombotic compound, process for their preparation, pharmaceutical compositions containing them and their use
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0303364A3 (en) Pyrimidine derivatives of arylalkane-sulfonamides having endothelin-antagonist activity, pharmaceutical compositions containing them and their use
HUP0204005A3 (en) Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them
HUP0200242A3 (en) Pyrazole-3-on-derivatives as factor xa inhibitors, pharmaceutical compositions containing them, their preparation and their use